Exposure to bacterial products renders macrophages highly susceptible to T-tropic HIV-1.
暂无分享,去创建一个
W Turner | A. Fauci | A S Fauci | M. Moriuchi | H. Moriuchi | H Moriuchi | M Moriuchi | W. Turner | A. Fauci | Hiroyuki Moriuchi | Willie Turner
[1] S. Kawamoto,et al. Isoquinolinesulfonamides, novel and potent inhibitors of cyclic nucleotide dependent protein kinase and protein kinase C. , 1984, Biochemistry.
[2] Huisman,et al. Differential syncytium-inducing capacity of human immunodeficiency virus isolates: frequent detection of syncytium-inducing isolates in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex , 1988, Journal of virology.
[3] B. Bennetts,et al. HIV-1 infection in an individual homozygous for the CCR5 deletion allele , 1997, Nature Medicine.
[4] M. Lederman,et al. Mycobacterium tuberculosis and its purified protein derivative activate expression of the human immunodeficiency virus. , 1994, Journal of acquired immune deficiency syndromes.
[5] Dominique Schols,et al. Amino-terminal Truncation of Chemokines by CD26/Dipeptidyl-peptidase IV , 1998, The Journal of Biological Chemistry.
[6] T. Schwartz,et al. Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. , 1997, Science.
[7] C. Cheng‐Mayer,et al. Host range, replicative, and cytopathic properties of human immunodeficiency virus type 1 are determined by very few amino acid changes in tat and gp120 , 1991, Journal of virology.
[8] A. Giannetti,et al. Langerhans cells and HIV infection. , 1995, Immunology today.
[9] A. Fauci,et al. Nuclear factor-kappa B potently up-regulates the promoter activity of RANTES, a chemokine that blocks HIV infection. , 1997, Journal of immunology.
[10] M. Martin,et al. Construction and characterization of a stable full-length macrophage-tropic HIV type 1 molecular clone that directs the production of high titers of progeny virions. , 1996, AIDS research and human retroviruses.
[11] H. Gendelman,et al. Trans-activation of the human immunodeficiency virus long terminal repeat sequence by DNA viruses. , 1986, Proceedings of the National Academy of Sciences of the United States of America.
[12] B. Levine,et al. Differential regulation of HIV-1 fusion cofactor expression by CD28 costimulation of CD4+ T cells. , 1997, Science.
[13] F. Negro,et al. Human herpes virus‐6 increases HIV‐1 expression in co‐infected T cells via nuclear factors binding to the HIV‐1 enhancer. , 1989, The EMBO journal.
[14] J. Albert,et al. The biological phenotype of HIV-1 is usually retained during and after sexual transmission. , 1994, Virology.
[15] G. Joø,et al. Macrophage tropism: fact or fiction? , 1997, Journal of leukocyte biology.
[16] J. Hoxie,et al. Inhibition of human immunodeficiency virus fusion by a monoclonal antibody to a coreceptor (CXCR4) is both cell type and virus strain dependent , 1997, Journal of virology.
[17] C. Cheng‐Mayer,et al. Biologic features of HIV-1 that correlate with virulence in the host. , 1988, Science.
[18] R. Connor,et al. Change in Coreceptor Use Correlates with Disease Progression in HIV-1–Infected Individuals , 1997, The Journal of experimental medicine.
[19] Anthony S. Fauci,et al. Host factors and the pathogenesis of HIV-induced disease , 1996, Nature.
[20] G. Nuovo,et al. In situ detection of polymerase chain reaction-amplified HIV-1 nucleic acids and tumor necrosis factor-alpha RNA in the central nervous system. , 1994, The American journal of pathology.
[21] J. Albert,et al. Dual tropism for macrophages and lymphocytes is a common feature of primary human immunodeficiency virus type 1 and 2 isolates , 1994, Journal of virology.
[22] A. Sica,et al. Bacterial Lipopolysaccharide Rapidly Inhibits Expression of C–C Chemokine Receptors in Human Monocytes , 1997, The Journal of experimental medicine.
[23] Y. Uehara,et al. Use and selectivity of herbimycin A as inhibitor of protein-tyrosine kinases. , 1991, Methods in enzymology.
[24] Lange,et al. Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome: studies on sequential HIV isolates , 1989, Journal of virology.
[25] Marc Parmentier,et al. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene , 1996, Nature.
[26] H. Gendelman,et al. Infection of macrophages with lymphotropic human immunodeficiency virus type 1 can be arrested after viral DNA synthesis , 1993, Journal of virology.
[27] Ying Sun,et al. The β-Chemokine Receptors CCR3 and CCR5 Facilitate Infection by Primary HIV-1 Isolates , 1996, Cell.
[28] R. Koup,et al. Macrophages and CD4+ T lymphocytes from two multiply exposed, uninfected individuals resist infection with primary non-syncytium-inducing isolates of human immunodeficiency virus type 1 , 1996, Journal of virology.
[29] R. Ulevitch,et al. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. , 1990, Science.
[30] R. Locksley,et al. Activation of human monocyte--derived macrophages with lipopolysaccharide decreases human immunodeficiency virus replication in vitro at the level of gene expression. , 1991, The Journal of clinical investigation.
[31] R. Puri,et al. Human Cytokines: Their Role in Disease and Therapy , 1995 .
[32] A. Arcaro,et al. Wortmannin is a potent phosphatidylinositol 3-kinase inhibitor: the role of phosphatidylinositol 3,4,5-trisphosphate in neutrophil responses. , 1993, The Biochemical journal.
[33] Virginia Litwin,et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5 , 1996, Nature.
[34] H. Schuitemaker,et al. HIV-1 macrophage tropism is determined at multiple levels of the viral replication cycle. , 1994, The Journal of clinical investigation.
[35] J. Albert,et al. REPLICATIVE CAPACITY OF HUMAN IMMUNODEFICIENCY VIRUS FROM PATIENTS WITH VARYING SEVERITY OF HIV INFECTION , 1986, The Lancet.
[36] M. Siekevitz,et al. Activation of the HIV-1 LTR by T cell mitogens and the trans-activator protein of HTLV-I. , 1987, Science.
[37] C. Katlama,et al. HIV-1 infection in an individual homozygous for CCR5▵32 , 1997, The Lancet.
[38] N. Reiner,et al. Altered cell signaling and mononuclear phagocyte deactivation during intracellular infection. , 1994, Immunology today.
[39] J J Goedert,et al. Genetic Restriction of HIV-1 Infection and Progression to AIDS by a Deletion Allele of the CKR5 Structural Gene , 1996, Science.
[40] J. Blackwell,et al. Opposing effects of interferon-gamma on iNOS and interleukin-10 expression in lipopolysaccharide- and mycobacterial lipoarabinomannan-stimulated macrophages. , 1995, Immunology.
[41] A. Sher,et al. Infection of human immunodeficiency virus 1 transgenic mice with Toxoplasma gondii stimulates proviral transcription in macrophages in vivo , 1996, The Journal of experimental medicine.
[42] A. Mindel. Virology and Immunology , 1989 .
[43] O. Bagasra,et al. CD14 is involved in control of human immunodeficiency virus type 1 expression in latently infected cells by lipopolysaccharide. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[44] S. Straus,et al. Varicella-zoster virus (VZV) virion-associated transactivator open reading frame 62 protein enhances the infectivity of VZV DNA. , 1994, Virology.
[45] H. Schuitemaker,et al. Monocytotropic human immunodeficiency virus type 1 (HIV-1) variants detectable in all stages of HIV-1 infection lack T-cell line tropism and syncytium-inducing ability in primary T-cell culture , 1991, Journal of virology.
[46] Paul E. Kennedy,et al. HIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled Receptor , 1996, Science.
[47] R. Ulevitch,et al. Lipopolysaccharide (LPS) partial structures inhibit responses to LPS in a human macrophage cell line without inhibiting LPS uptake by a CD14- mediated pathway , 1992, The Journal of experimental medicine.
[48] D. Ho,et al. Genotypic and phenotypic characterization of HIV-1 patients with primary infection. , 1993, Science.
[49] A. Tomasz,et al. CD14 is a pattern recognition receptor. , 1994, Immunity.
[50] J. Albert,et al. Transmission of human immunodeficiency virus type 1 (HIV-1) from mother to child correlates with viral phenotype. , 1993, Virology.
[51] P. Tassone,et al. Epstein-Barr virus nuclear antigen 2 transactivates the long terminal repeat of human immunodeficiency virus type 1 , 1993, Journal of virology.
[52] Richard A Koup,et al. Homozygous Defect in HIV-1 Coreceptor Accounts for Resistance of Some Multiply-Exposed Individuals to HIV-1 Infection , 1996, Cell.
[53] H. Friedman,et al. An infectious molecular clone of an unusual macrophage-tropic and highly cytopathic strain of human immunodeficiency virus type 1 , 1992, Journal of virology.
[54] A. Fauci,et al. Cloning and analysis of the promoter region of CCR5, a coreceptor for HIV-1 entry. , 1997, Journal of immunology.
[55] C. Broder,et al. Fusogenic selectivity of the envelope glycoprotein is a major determinant of human immunodeficiency virus type 1 tropism for CD4+ T-cell lines vs. primary macrophages. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[56] B. Walker,et al. β-Chemokines are released from HIV-1-specific cytolytic T-cell granules complexed to proteoglycans , 1998, Nature.
[57] G. Nuovo,et al. Human Immunodeficiency Virus Type 1 T-Lymphotropic Strains Enter Macrophages via a CD4- and CXCR4-Mediated Pathway: Replication Is Restricted at a Postentry Level , 1998, Journal of Virology.
[58] T. Mustelin,et al. T cell antigen receptor-mediated activation of phospholipase C requires tyrosine phosphorylation. , 1990, Science.
[59] A. Fauci,et al. Factors Secreted by Human T Lymphotropic Virus Type I (HTLV-I)–infected Cells Can Enhance or Inhibit Replication of HIV-1 in HTLV-I–uninfected Cells: Implications for In Vivo Coinfection with HTLV-I and HIV-1 , 1998, The Journal of experimental medicine.
[60] M. Bukrinsky,et al. Chemokines and HIV replication , 1996, Nature.
[61] J. Orenstein,et al. Immune stimulation and HIV‐1 viral replication , 1997, Journal of leukocyte biology.
[62] C. Mackay,et al. The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[63] A. Fauci,et al. Differentiation of Promonocytic U937 Subclones into Macrophagelike Phenotypes Regulates a Cellular Factor(s) Which Modulates Fusion/Entry of Macrophagetropic Human Immunodeficiency Virus Type 1 , 1998, Journal of Virology.
[64] C. Winkler,et al. HIV-1 infection in a man homozygous for CCR5▵32 , 1997, The Lancet.
[65] C. Fox,et al. Macrophages as a source of HIV during opportunistic infections. , 1997, Science.
[66] A. Fauci,et al. Cloning and analysis of the promoter region of CXCR4, a coreceptor for HIV-1 entry. , 1997, Journal of immunology.
[67] Kees,et al. Macrophage-tropic variants initiate human immunodeficiency virus type 1 infection after sexual, parenteral, and vertical transmission. , 1994, The Journal of clinical investigation.
[68] Marc Parmentier,et al. A Dual-Tropic Primary HIV-1 Isolate That Uses Fusin and the β-Chemokine Receptors CKR-5, CKR-3, and CKR-2b as Fusion Cofactors , 1996, Cell.
[69] H. Gendelman,et al. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone , 1986, Journal of virology.
[70] S. Amar,et al. Involvement of protein kinase C and protein tyrosine kinase in lipopolysaccharide-induced TNF-alpha and IL-1 beta production by human monocytes. , 1994, Journal of immunology.
[71] D. Baltimore,et al. Lipopolysaccharide is a potent monocyte/macrophage-specific stimulator of human immunodeficiency virus type 1 expression , 1990, The Journal of experimental medicine.
[72] M. Kazatchkine,et al. Membrane molecules which trigger the production of interleukin‐1 and tumor necrosis factor‐α by lipopolysaccharide‐stimulated human monocytes , 1992, European journal of immunology.
[73] J. Blackwell,et al. Macrophage activation: lipoarabinomannan from avirulent and virulent strains of Mycobacterium tuberculosis differentially induces the early genes c-fos, KC, JE, and tumor necrosis factor-alpha. , 1993, Journal of immunology.
[74] A. Fauci,et al. CD8+ T-cell-derived soluble factor(s), but not beta-chemokines RANTES, MIP-1 alpha, and MIP-1 beta, suppress HIV-1 replication in monocyte/macrophages. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[75] S. Wright,et al. Molecules from Staphylococcus aureus that bind CD14 and stimulate innate immune responses , 1995, The Journal of experimental medicine.
[76] D. Burke,et al. Efficient isolation and propagation of human immunodeficiency virus on recombinant colony-stimulating factor 1-treated monocytes , 1988, The Journal of experimental medicine.
[77] Stephen C. Peiper,et al. Identification of a major co-receptor for primary isolates of HIV-1 , 1996, Nature.
[78] D. Weissman,et al. Role of dendritic cells in immunopathogenesis of human immunodeficiency virus infection , 1997, Clinical microbiology reviews.
[79] C. Katlama,et al. HIV-1 infection in an individual homozygous for CCR5 delta 32. Seroco Study Group. , 1997, Lancet.
[80] C. Broder,et al. CC CKR5: A RANTES, MIP-1α, MIP-1ॆ Receptor as a Fusion Cofactor for Macrophage-Tropic HIV-1 , 1996, Science.
[81] D. Richman,et al. Interferons and bacterial lipopolysaccharide protect macrophages from productive infection by human immunodeficiency virus in vitro , 1989, The Journal of experimental medicine.
[82] J. Hoxie,et al. Promonocytic U937 subclones expressing CD4 and CXCR4 are resistant to infection with and cell-to-cell fusion by T-cell-tropic human immunodeficiency virus type 1 , 1997, Journal of virology.